Compare NATR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | MXCT |
|---|---|---|
| Founded | 1972 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.4M | 155.8M |
| IPO Year | 1995 | 2021 |
| Metric | NATR | MXCT |
|---|---|---|
| Price | $10.23 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $16.50 | $4.11 |
| AVG Volume (30 Days) | 190.8K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $480,144,000.00 | $33,026,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | $2.59 | $10.06 |
| P/E Ratio | $17.68 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $9.38 | $0.64 |
| 52 Week High | $28.14 | $1.80 |
| Indicator | NATR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 32.58 | 49.36 |
| Support Level | $9.38 | $1.02 |
| Resistance Level | $12.99 | $1.54 |
| Average True Range (ATR) | 0.57 | 0.15 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 22.57 | 37.23 |
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.